Home Feature Mechanisms of relevancy: Lessons from Pharmacy, viagra, and rethinking

Mechanisms of relevancy: Lessons from Pharmacy, viagra, and rethinking

0
41

 

 

By Muhammad Oladipupo Salaudeen

As one of the last sets of students who will be awarded the Bachelor of Pharmacy (B.Pharm) degree, questions like “Is B.Pharm still worth it?” “Which is better: B.Pharm or Pharm.D?” and “What is our fate after postgraduate studies?” never leave our discussions. They are discussed during long lectures, in practicals and during breaks. They are the never-ending thoughts behind our chatter, giggles and noise.

Though understandable, I am neither here to allay your fears nor establish the supremacy of one over the other. It is irrelevant, and I do not intend to waste your time on such matters. After all, time is money.

However, on this subject, I am willing to lend you a pair of spectacles, different from the ones you have in your closet. I hope you will be kind enough to put them on.

The art of rethinking

One of the best skills to have is the ability to rethink. Yes, rethinking. It is an unconventional process of reviewing previously made decisions to change or improve them. It is like going back to where you had bid them goodnight.

To rethink is to think again.

Rethinking enables one to be open-minded; for one’s mind not to be built like a wall but a window, where ideologies undergo constant reassessment like ventilation. This is what the pioneers of Doctor of Pharmacy (Pharm.D) education did. They saw the need for the pharmacy profession to expand beyond its traditional compounding and dispensing roles.

It seems they took the wisdom in the lyrics of Fuji musician Taye Currency when he said, “Baye ba n yìí kaa ma baye yìí, bigba ba n yìí kaa ma ba gba yii, ẹnití o bá gbà yi, olùwà rẹ a bagba lọ,” meaning that we should change and adapt as the world and time change, because those who refuse to adapt will be left behind.

Contrary to some opinions, Pharm.D is not a replacement for B.Pharm but an evolutionary product: a movement from product-oriented practice to patient-oriented care. It is a tall order that involves an enormous amount of rethinking.

So, what can we learn from this?

Pharmacy has always evolved

Pharmacy as a profession, since time immemorial, has undergone a series of evolutions in accordance with each era. In fact, B.Pharm itself is an outcome of rethinking because it arose to fill a gap left by a previous model.

The product-oriented era gained prominence in the early 20th century and expanded after the Second World War, following the explosion of new medicines. Individuals were trained to prepare, compound and dispense drugs.

However, by the 1950s, pharmacy practice was becoming more clinical without completely losing its product-oriented character. Institutions such as the University of Southern California and the University of California, San Francisco, were among the pioneers of this transformation.

Before this clinical era, which eventually gave rise to the Doctor of Pharmacy degree, the pharmacist’s responsibility largely ended at the counter: dispense and go.

Pharmaceutical care changed that. It introduced follow-up, monitoring and counselling, among other responsibilities. Pharmacists became equipped with clinical knowledge that enabled them to participate in clinical decisions alongside other healthcare professionals.

Given that pharmacists are among the most accessible health professionals, this new programme sought to equip pharmacists with competencies that the traditional B.Pharm curriculum did not emphasise to the same extent, including health education, disease screening, disease management and counselling.

This is a classic example of instructional rethinking. And it can be applied to both the micro and macro elements of our lives.

Intellectual humility as foundation

Rethinking often begins with intellectual humility: the subtle act of admitting the gaps in your knowledge. It is the ability to say, “I don’t know this,” or, “I lack sufficient knowledge or evidence to make this decision.”

Acknowledging one’s lapses is not a sign of weakness or stupidity. Rather, it demonstrates the ability to find strength through our weaknesses. Confident humility acts as a stimulant for doubt, which opens the door to curiosity. Like the cat whose curiosity led to its demise nine times but was resurrected on every occasion, asking the right questions follows the same mechanism: it causes the death of ignorance and the resurrection of beneficial knowledge.

Even the Bible attests to the transformative power of questions, especially the right ones. Matthew 7:7 says, “Ask, and it shall be given you; seek, and ye shall find; knock, and it shall be opened unto you.”

Humility takes us to the wall of our ignorance, but questions tear down that wall. However, these two are incomplete without the third ingredient: finding answers to the questions.

The traps in seeking answers

This stage is delicate because of the numerous traps it houses. In the process of persistent seeking (ìwákùwá), mess (ìríkùrí) and pleasant images (ìrígidí) will be encountered. The ability to distinguish and properly separate them into independent strands is a must.

At this stage, there are two traps into which one is likely to fall: confirmation bias and desirability bias. These concepts have been explored extensively by psychologists, including Daniel Kahneman, and popularised in contemporary discussions by writers such as Adam Grant. The former refers to the tendency to seek information that confirms what we already expect to see, while the latter describes the tendency to favour what we want to see.

These biases can nullify our efforts on the search journey, causing us to remove the scientist’s goggles from our eyes because feelings are placed over facts, and comfort over truth.

Doses of humility will make us embrace all answers, comfortable or not, and prevent us from cherry-picking those that align with our existing thoughts.

Rethinking through pharmacology

The act of rethinking how to rethink is itself an example of rethinking. It is not meant to be rigid but flexible. However, its flexibility should accommodate some fixed frameworks to prevent distorted rethinking.

Providing these guides is what I intend to do above, not to show you how to think again.

The first time I heard about drug repurposing was two weeks ago, while researching an assignment given to us on the subject. I realised that drug repurposing is a pharmacological version of rethinking: thinking again in pharmacokinetic and pharmacodynamic terms.

In drug development, drug repurposing simply refers to the process of finding new uses for existing drugs. It involves redesigning a drug’s destiny. Think of it like a machete that was primarily designed to clear the bush, but whose other functions, such as chopping firewood or settling a boundary dispute, were later discovered. The latter functions then become just as relevant, or perhaps more valuable, in a different context.

Sildenafil provides a classic example. In the 1980s, sildenafil was developed by Pfizer as a potential treatment for angina pectoris and other cardiovascular conditions. During clinical trials, however, male participants reported an unexpected effect: erections. Scientists did not simply ignore this unexpected observation. They investigated it, rethought the drug’s potential and explored a new therapeutic application.

That work eventually led to sildenafil being approved for erectile dysfunction in March 1998 under the brand name Viagra. A few years later, sildenafil underwent another transformation and was approved by the United States Food and Drug Administration as Revatio for the treatment of pulmonary arterial hypertension (PAH).

What is behind this ever-evolving wonder drug? The answer is the scientists, whose rethinking glasses are always on. They are the “alatọkun”, the masquerade handlers, behind the “eegun”, making it dance to the changing tunes of the drum. They were confidently humble enough to recognise new possibilities arising from the unexpected findings during clinical trials. They went down the rabbit hole to seek answers to the apparent abnormality and, in doing so, discovered and explored a new side of sildenafil.

Do not be surprised if, in the near future, sildenafil is used for “financial hypoglycaemia” or “chronic sapa disease”.

Ask yourself: what actually needs to be rethought in my life?

This exercise may help us discover numerous approaches to different facets of our lives, just like Pharm.D and sildenafil.

Beyond the B.Pharm debate

To my colleagues who will soon be awarded a B.Pharm degree, my comrades-in-struggle, juggling demonic structures and synthesis in pharmaceutical chemistry to “-cology”, nauseating MOAs, I will leave you with this:

Wear the B.Pharm tag with pride. You deserve it.

A degree is not the sole determinant of your relevance; your willingness to evolve is.

Learn not only sildenafil’s mechanisms of action, but also the mechanisms of relevancy.

Embrace flexibility. Adopt range.

The question should not be whether B.Pharm is still worth it, but how I can integrate the lessons from Pharm.D and sildenafil into my life.

Keep rethinking, even this piece.

Remember: with a dosage of humility and wisdom.

LEAVE A REPLY

Please enter your comment!
Please enter your name here